137 related articles for article (PubMed ID: 31818164)
1. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
[No Abstract] [Full Text] [Related]
2. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
5. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
6. All-cause and disease-related health care costs associated with recurrent venous thromboembolism.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Hossou Y; Schein J; Kaatz S
Thromb Haemost; 2013 Dec; 110(6):1288-97. PubMed ID: 24085327
[TBL] [Abstract][Full Text] [Related]
7. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
Casciano JP; Dotiwala Z; Kemp R; Li C; Cai J; Preblick R
Am J Health Syst Pharm; 2015 Feb; 72(4):291-300. PubMed ID: 25631836
[TBL] [Abstract][Full Text] [Related]
9. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
[TBL] [Abstract][Full Text] [Related]
10. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
[TBL] [Abstract][Full Text] [Related]
11. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
[TBL] [Abstract][Full Text] [Related]
13. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
[TBL] [Abstract][Full Text] [Related]
14. Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J
Support Care Cancer; 2019 Oct; 27(10):3833-3840. PubMed ID: 30734088
[TBL] [Abstract][Full Text] [Related]
15. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
16. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
18. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs of patients with cancer stratified by Khorana score risk levels.
Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
J Med Econ; 2021; 24(1):866-873. PubMed ID: 34181497
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
